Gyre Therapeutics (GYRE) Cash from Operations Growth (3y) (2013 - 2026)
Gyre Therapeutics (GYRE) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -0.27% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 52.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.09% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 6.22% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 96.08% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.23% |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -78.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -78.58% |
| Mar 31, 2026 | -32.53% |
| Dec 31, 2025 | -28.71% |
| Sep 30, 2025 | 38.07% |
| Jun 30, 2025 | 29.53% |
| Mar 31, 2025 | 77.96% |
| Dec 31, 2024 | 46.16% |
| Sep 30, 2024 | 27.65% |
| Jun 30, 2024 | 35.13% |
| Mar 31, 2024 | 28.43% |
| Dec 31, 2023 | 29.11% |
| Sep 30, 2023 | 37.20% |
| Jun 30, 2023 | 31.99% |
| Mar 31, 2023 | 61.02% |
| Dec 31, 2022 | 93.36% |
| Sep 30, 2022 | 7.18% |
| Jun 30, 2022 | -2.35% |
| Mar 31, 2022 | 6.95% |
| Dec 31, 2021 | -25.18% |
| Sep 30, 2021 | -45.43% |